Glenmark launches antiviral drug Favipiravir for treatment of mild to moderate COVID-19 patients

Hyderabad: In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, on Saturday announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients.
Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu® the first oral Favipiravir-approved medication in India for the treatment of COVID-19, the Pharmaceutical company said in a statement.
Favipiravir is backed by strong clinical evidence showing encouraging results in patients with mild to moderate COVID-19, it said the antiviral offers broad spectrum RNA virus coverage with clinical improvement noted across age groups 20 to 90 years.
Favipiravir can be used in COVID-19 patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID 19 symptoms, the pharmaceutical company said .
It offers rapid reduction in viral load within four days and provides faster symptomatic and radiological improvement.
Of most importance, Favipiravir has shown clinical improvement of up to 88 per cent in COVID-19 mild to moderate COVID 19 cases.
Glenmark successfully developed the Active Pharmaceutical Ingredient (API) and the formulation for FabiFlu® through its own in-house R&D team.
Glenmark filed the product for clinical trial with India’s drug regulator DCGI and became the first pharmaceutical company in India to receive approval for conducting phase 3 clinical trials on mild to moderate COVID-19 patients.
Commenting on the significance of this development, Glenmark Chairman and Managing Director Mr. Glenn Saldanha, said,“we hope the availability of an effective treatment such as FabiFlu® will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option.”
Glenmark will work closely with the government and medical community to make FabiFlu® quickly accessible to patients across the country, he added.
Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.
Most patients exhibiting mild to moderate symptoms can benefit from FabiFlu® use. The drug will be available as a prescription-based medication for INR 103/tablet, with recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14. (UNI)